JAK1 and 2 Inhibitor
Catalog No. J01-901
Catalog No. | Pack Size | Price (USD) | |
---|---|---|---|
J01-901-05 | 5 mg | $90 | |
J01-901-25 | 25 mg | $225 | |
J01-901-BULK | BULK | Contact Us |
Overview:
Potent and selective JAK1&2 inhibitor, IC50s=2.7, 4.5 and 322 nM forJAK1, JAK2 and JAK3 respectively1. Blocks IL-6 signaling (IC50=281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50=127 nM)2. Inhibits the proinflammatory secretome of senescent cells3. The JAK1 S646P mutant is highly sensitive to ruxolitinib4. Clinically useful anticancer agent.
References:
1. S Verstovsek et al. Hematol. Am. Soc. Hematol. Educ. Program 2009 2009(1)636
2. A Quintas-Cardama et al. Blood 2010 115:3109
3. JN Farr et al. Nat. Med. 2017 23:1072
4. Q Li et al. Oncotarget 2017 8:34687
CAS Registry Number:
941678-49-5
Molecular Formula:
C17H18N6
Appearance:
White powder
Molecular Weight:
306.4
Purity:
>98% (HPLC,TLC); NMR (conforms)
Solubilization:
May be dissolved in DMSO (28 mg/ml) or ethanol (15 mg/ml warm)
Aliases:
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
Storage and Stability:
Store desiccated as supplied at -20oC for up to 2 year. Store solutions at -20oC for up to 3 months.
Molecular Structure:
There are no related publications available for this product.
Cancer, Cardiovascular Disease, Cytoplasmic Tyrosine Kinases, Inflammation, JAK/STAT Pathway
STAY CONNECTED
Fax: 1-604-232-4601